AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23369009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified plaster of Paris cast
Number of subjects: 70
Study 23369009 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchcast boot
Number of subjects: 70
Study 23369009 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 22646524 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-alcohol message
Number of subjects: 84
Study 22646524 — intervention group
Group type: COMPARATOR
Intervention: No alcohol message exposure
Number of subjects: 84
Study 19941048 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐administered Cognitive‐Behavioral Therapy (T‐CBT)
Number of subjects: 127
Study 19941048 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐administered Emotion‐Focused Therapy (T‐EFT)
Number of subjects: 127
Study 18401810 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training program (resistance, flexibility, joint mobility, balance/coordination exercises)
Number of subjects: 16
Study 18401810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 15986275 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AM) alone
Number of subjects: 23
Study 15986275 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AM) with 0.02% Mitomycin C (MMC)
Number of subjects: 23
Study 14641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy before the age of 4 years
Number of subjects: 1777
Study 14641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy at an early age
Number of subjects: 1777
Study 14641605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy due to recurrent otitis media
Number of subjects: 1777
Study 14641605 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who underwent probing of the nasolacrimal duct)
Number of subjects: 1777
Study 12585542 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-dependent methods based on permutations of the data (ordinary least squares regression)
Number of subjects: 0
Study 12585542 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-dependent methods based on permutations of the data (least absolute deviations regression)
Number of subjects: 0
Study 12585542 — intervention group
Group type: COMPARATOR
Intervention: Data-dependent methods (six approaches)
Number of subjects: 0
Study 10086671 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM)
Number of subjects: 119
Study 10086671 — intervention group
Group type: COMPARATOR
Intervention: 10 days of omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., and metronidazole 400 mg t.d.s. (OAM) plus compliance enhancing measures
Number of subjects: 119
Study 10086671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OAM and OAM plus compliance enhancing measures)
Number of subjects: 119
Study 7545889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 133
Study 7545889 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 133
Study 1896092 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxyvitamin D3 (24,25(OH)2D3)
Number of subjects: 20
Study 1896092 — intervention group
Group type: COMPARATOR
Intervention: 1 alpha-OH-D3 and calcium carbonate (existing treatment)
Number of subjects: 20
Study 7013968 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (Haldol)
Number of subjects: 64
Study 7013968 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzquinamide (Emetecon)
Number of subjects: 64
Study 6367434 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg four times a day
Number of subjects: 19
Study 6367434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28370958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottled spring water certified by Sri Lanka Standard (SLS) for a period of 18 months
Number of subjects: 0
Study 28370958 — intervention group
Group type: COMPARATOR
Intervention: Usual drinking water
Number of subjects: 0
Study 26590810 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalangeal BMD measurement using a portable scanner
Number of subjects: 121
Study 26590810 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalangeal BMD measurement
Number of subjects: 121
Study 26590810 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage approach
Number of subjects: 121
Study 24755124 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet with food
Number of subjects: 0
Study 24755124 — intervention group
Group type: COMPARATOR
Intervention: FDC tablet without food
Number of subjects: 0
Study 24755124 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablets with normal dissolution characteristics
Number of subjects: 0
Study 24755124 — intervention group
Group type: COMPARATOR
Intervention: FDC tablets with slower dissolution characteristics
Number of subjects: 0
Study 23711168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for pain and insomnia (CBT-PI)
Number of subjects: 367
Study 23711168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for pain (CBT-P)
Number of subjects: 367
Study 23711168 — intervention group
Group type: COMPARATOR
Intervention: Education-only control (EOC)
Number of subjects: 367
Study 20211222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cholinergic bronchodilator (ipratropium bromide)
Number of subjects: 54
Study 20211222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall thickness
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall pattern
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for bowel wall blood flow
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for enlarged mesenteric lymph nodes
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for abdominal free fluid
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for mesenteric hypertrophy
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for stenosis
Number of subjects: 20
Study 18583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ultrasonography for fistula
Number of subjects: 20
Study 16633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6 g/d
Number of subjects: 90
Study 16633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG 16 billion/d for 15 d/mo
Number of subjects: 90
Study 16633103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6 g/d + Lactobacillus casei DG 16 billion/d for 15 d/mo
Number of subjects: 90
Study 16633103 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 90
Study 12505566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation for ISR in SVGs
Number of subjects: 1142
Study 12505566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation for ISR in native coronary arteries
Number of subjects: 1142
Study 11074833 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent GABHS tonsillopharyngitis of the same serotype
Number of subjects: 60
Study 11074833 — intervention group
Group type: COMPARATOR
Intervention: Initial GABHS infection
Number of subjects: 60
Study 8930427 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (granules from a 30‐mg capsule mixed with apple juice and administered through a nasogastric tube)
Number of subjects: 22
Study 8930427 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (an intact 30‐mg capsule)
Number of subjects: 22
Study 1528957 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus Mianserin (30 mg daily)
Number of subjects: 40
Study 1528957 — intervention group
Group type: COMPARATOR
Intervention: Imipramine alone (placebo control)
Number of subjects: 40
Study 3987221 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release pseudoephedrine formulations
Number of subjects: 38
Study 3987221 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal controlled-release formulation from single-dose study
Number of subjects: 38
Study 3987221 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release pseudoephedrine hydrochloride
Number of subjects: 38
Study 3987221 — intervention group
Group type: COMPARATOR
Intervention: Reference pseudoephedrine hydrochloride syrup
Number of subjects: 38
Study 29555812 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP decision support video
Number of subjects: 450
Study 25877234 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 29
Study 25877234 — intervention group
Group type: COMPARATOR
Intervention: Bur preparation
Number of subjects: 29
Study 25877234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Er:YAG laser and Bur preparation)
Number of subjects: 29
Study 24216598 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (10-min duration, every weekday for 3 weeks)
Number of subjects: 55
Study 24216598 — intervention group
Group type: COMPARATOR
Intervention: Quiet presence (control group, every weekday for 3 weeks)
Number of subjects: 55
Study 24216598 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 55
Study 24216598 — intervention group
Group type: COMPARATOR
Intervention: Quiet presence (control group)
Number of subjects: 55
Study 22694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website intervention
Number of subjects: 603
Study 22694878 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 603
Study 20126343 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (EA) group (n=40)
Number of subjects: 80
Study 20126343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar plexus-sciatic nerve blocks (LPSB) group (n=40)
Number of subjects: 80
Study 18509873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 18509873 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonanxious controls)
Number of subjects: 0
Study 15684902 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling through 3‐Fr PICC devices
Number of subjects: 204
Study 15684902 — intervention group
Group type: COMPARATOR
Intervention: No blood sampling through 3‐Fr PICC devices (Control)
Number of subjects: 204
Study 12853831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant with lidocaine
Number of subjects: 20
Study 12853831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lubricant without lidocaine)
Number of subjects: 20
Study 11194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol for non‐oncologic chronic pain
Number of subjects: 52
Study 11194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol for postoperative acute pain
Number of subjects: 52
Study 11194981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol for oncologic chronic pain
Number of subjects: 52
Study 8618434 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine- and high-dose cytarabine-containing regimens
Number of subjects: 144
Study 1464897 — intervention group
Group type: EXPERIMENTAL
Intervention: Saiko-ka-ryukotsuboreito (S)
Number of subjects: 30
Study 1464897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai‐saiko‐to (D)
Number of subjects: 30
Study 6434367 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of LactAid added to milk
Number of subjects: 50
Study 6434367 — intervention group
Group type: COMPARATOR
Intervention: Prehydrolyzed milk
Number of subjects: 50
Study 6434367 — intervention group
Group type: COMPARATOR
Intervention: Intact milk
Number of subjects: 50
Study 29902286 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010
Study 29902286 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010
Study 29902286 — intervention group
Group type: COMPARATOR
Intervention: Sequential strategy (letrozole followed by tamoxifen)
Number of subjects: 8010
Study 28296055 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 488
Study 28296055 — intervention group
Group type: COMPARATOR
Intervention: acarbose
Number of subjects: 488
Study 26654625 — intervention group
Group type: EXPERIMENTAL
Intervention: Star Wars music (SWM)
Number of subjects: 103
Study 26654625 — intervention group
Group type: COMPARATOR
Intervention: endoscopist-selected popular music (PM)
Number of subjects: 103
Study 23442547 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (compensating extraction of the upper first permanent molar)
Number of subjects: 400
Study 23442547 — intervention group
Group type: COMPARATOR
Intervention: Removal of lower first permanent molars but no extraction of the upper
Number of subjects: 400
Study 21042881 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (1.0 g/kg)
Number of subjects: 9
Study 21042881 — intervention group
Group type: COMPARATOR
Intervention: 23.4% saline (0.686 mL/kg)
Number of subjects: 9
Study 21042881 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 9
Study 21042881 — intervention group
Group type: COMPARATOR
Intervention: 23.4% saline
Number of subjects: 9
Study 21042881 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol and 23.4% saline
Number of subjects: 9
Study 18704963 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) applied during wound closure
Number of subjects: 52
Study 18704963 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP)
Number of subjects: 52
Study 18704963 — intervention group
Group type: COMPARATOR
Intervention: Saline applied in controls
Number of subjects: 52
Study 16608860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy during ICU stay
Number of subjects: 970
Study 16608860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy during ICU stay (with at least 3 days of insulin therapy)
Number of subjects: 970
Study 16608860 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 970
Study 16608860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 970
Study 12941725 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 132
Study 12941725 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 132
Study 10903605 — intervention group
Group type: EXPERIMENTAL
Intervention: CIP+MET
Number of subjects: 459
Study 10903605 — intervention group
Group type: COMPARATOR
Intervention: PIP/TAZO
Number of subjects: 459
Study 8840756 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 50
Study 8840756 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study 1290431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral nifedipine
Number of subjects: 24
Study 1290431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1290431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous hydralazine
Number of subjects: 24
Study 6746322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A (10,000 micrograms/d) for 4 weeks
Number of subjects: 37
Study 6746322 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 sex-matched healthy subjects)
Number of subjects: 37
Study 30999324 — intervention group
Group type: EXPERIMENTAL
Intervention: Junfeng BFS Water (JBW)
Number of subjects: 60
Study 30999324 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated water)
Number of subjects: 60
Study 29135709 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival lidocaine and proparacaine drops as needed during surgery
Number of subjects: 45
Study 29135709 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 45
Study 29135709 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel
Number of subjects: 45
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: ddTMZ + isotretinoin doublet
Number of subjects: 155
Study 25239666 — intervention group
Group type: COMPARATOR
Intervention: ddTMZ alone
Number of subjects: 155
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet regimens
Number of subjects: 155
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet regimens
Number of subjects: 155
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 155
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin-containing regimens
Number of subjects: 155
Study 25239666 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib or thalidomide combinations
Number of subjects: 155
Study 24429164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg
Number of subjects: 3
Study 24429164 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg
Number of subjects: 3
Study 24429164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 22622672 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone–deferoxamine (DFP‐DFO)
Number of subjects: 0
Study 22622672 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone (DFP) alone
Number of subjects: 0
Study 19571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (34 ± 26 mg/day)
Number of subjects: 143
Study 19571802 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of atorvastatin
Number of subjects: 143
Study 17519550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopy
Number of subjects: 42
Study 17519550 — intervention group
Group type: COMPARATOR
Intervention: External ventricular drainage
Number of subjects: 42
Study 15555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 18
Study 15555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Menses phase
Number of subjects: 18
Study 15555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 18
Study 11425971 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualized SLNs
Number of subjects: 136
Study 11425971 — intervention group
Group type: COMPARATOR
Intervention: Nonvisualized SLNs
Number of subjects: 136
Study 11425971 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with nonvisualized SLNs
Number of subjects: 136
Study 9875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous display of trend data
Number of subjects: 0
Study 9875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating 24‐hr display of trend data, starting with display in first 24 hrs
Number of subjects: 0
Study 9875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating 24‐hr display of trend data, starting with no display in first 24 hrs
Number of subjects: 0
Study 9875920 — intervention group
Group type: COMPARATOR
Intervention: No display of trend data
Number of subjects: 0
Study 9875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff questionnaires
Number of subjects: 0
Study 9875920 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent questionnaires
Number of subjects: 0
Study 9133199 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository 100 mg
Number of subjects: 137
Study 9133199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac IM injection 30 mg
Number of subjects: 137
Study 9133199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two placebos)
Number of subjects: 137
Study 2251987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 2 million units as an intravenous bolus before hospital admission (group A)
Number of subjects: 78
Study 2251987 — intervention group
Group type: COMPARATOR
Intervention: Urokinase 2 million units as an intravenous bolus after hospital admission (group B)
Number of subjects: 78
Study 2251987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (group A)
Number of subjects: 78
Study 2251987 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (group B)
Number of subjects: 78
Study 543890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (10‐methoxy‐1,6‐dimethyl‐ergoline‐8 beta‐methanol‐(5‐bromonicotinate))
Number of subjects: 0
Study 543890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxin-mesylate (DHETM)
Number of subjects: 0
Study 543890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation operated by a low vision therapist
Number of subjects: 60
Study 31542748 — intervention group
Group type: COMPARATOR
Intervention: Current self-training standard provided by the device vendor
Number of subjects: 60
Study 31542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 60
Study 26715771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 40% of maximal inspiratory pressure (P(Imax)) for 6 weeks
Number of subjects: 30
Study 26715771 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (5% of P(Imax)) for 6 weeks
Number of subjects: 30
Study 23545807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 2.5 g
Number of subjects: 55
Study 23545807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 5 g
Number of subjects: 55
Study 23545807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 10 g
Number of subjects: 55
Study 23545807 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 55
Study 21753726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of xenon
Number of subjects: 40
Study 19082641 — intervention group
Group type: EXPERIMENTAL
Intervention: SabreSource system
Number of subjects: 60
Study 19082641 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy guidance alone
Number of subjects: 60